HT Vista Expands Into Europe And The USA Via New VetFamily Partnership
5 months ago 
551 views
HT Vista has partnered with the VetFamily community to expand the use of their innovative skin mass screening device to practices across Europe and the USA. Following a successful trial partnership resulting in the HT Vista device being adopted by clinics in Germany and Sweden they will be launching for more members in Europe and the USA in January 2024, with other countries to follow.
In partnership with the VetFamily team, HT Vista will be able to promote and share the benefits of their device with over 7000 independent practices across 11 countries, helping to bring the new technology to consulting rooms around the world.
The VetFamily platform is one of the largest animal health communities in the world and aims to empower the independent veterinarians to stay competitive and relevant in a fast moving and changing environment. By providing an innovative, easy-to-use, evidence-based device for screening dermal and subcutaneous masses, HT Vista offers practices the opportunity to detect malignant masses sooner and enhance treatment outcomes.
Commercial Partner Manager at VetFamily, Mr Anton Axelsson, comments “It’s wonderful to have HT Vista on board and we’re looking forward to working with them as they continue to expand in 2024.” He continues, “We’re always aiming to support our members as they expand the services they offer, and we hope they’ll be as excited by the new device as we are. This is a huge step forward for cancer-screening in dogs and we look forward to seeing more practices adopt the device as we help to spread the word.”
Expansion to practices abroad will be facilitated by HT Vista’s remote demonstration and installation processes. They currently offer both in-person and online demonstrations in the UK, and the success of the online demonstrations has prompted them to be made more widely available as part of the company’s expansion.
Liron Levy-Hirsch, Managing Director of HT Vista, is keen to start the next phase of the device’s rollout. “The last year has seen the HT Vista device being adopted by a growing number of practices across the UK, and this growth looks set to continue in 2024. We’ve been thrilled by the veterinary response to this new technology and we’re looking forward to offering it to the European and US markets as partners with VetFamily.”
He continues, “Our goal has always been to promote early diagnosis of malignant skin tumours, and we’ve already received so much positive feedback on this from practices. Having completed a successful one-month trial partnership with VetFamily we’ve already had clinics from Germany and Sweden sign up for the device, and we can’t wait to see its impact as we continue to expand in 2024.”
To find out more about the HT Vista device or book a demonstration, visit their website www.ht-vista.uk.
More from HT Vista
- HT Vista return to BSAVA to celebrate a successful first year with big giveaway
- New app helps vets and nurses further improve cancer screening device
- Newly published paper validates innovative AI-powered screening device for canine dermal and subcutaneous masses
- HT Vista celebrates a successful first month and prepares to showcase at BVA Live
